Skip to main content
Caplight Logo









Unobravo

Unobravo

Private
NaplesHealthcare & Life Scienceshttps://unobravo.com

Last Round

Growth Equity

Dec 13, 2023

Est. Valuation

$189M

Total Funding Raised

$17.53M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Unobravo is a healthcare company that provides an online mental health platform connecting patients with psychologists and psychotherapists for remote therapy sessions.

Sector

Healthcare & Life Sciences

Verticals

Mental Health, Telemedicine, HR

Business Model

B2C

Customer Profile

Subscription SaaS, Services & Consulting

AI Layer

Application

Keywords

online therapytelehealthmental health platformtelepsychologyemployee assistance programEAPvirtual therapycorporate wellnessdigital mental healththerapy marketplaceremote counselingemployee well-beingmatching algorithmB2B mental health

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Unobravo Comparables

Compare Unobravo with similar companies based on industry and business-model similarity.

Unobravo comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Serenis
87%
Teladoc Health, Inc.
79%
Mindler
78%

Unobravo Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Growth EquityDec 13, 2023
Series AJul 21, 2022
Pre SeedJan 1, 2020

Key People

Founding team and executive leadership

Danila De Stefano

CEO And Founder

Founding Team

Paolo Savini Nicci

Group CFO

Executive Team

Gregorio Maria Diodovich

Chief Operating Officer

Executive Team

Unobravo Investors

Notable investors and investment history

Unobravo investors
InvestorRounds
H14Growth Equity
SocialFare SeedPre Seed
NorthzoneGrowth Equity
CDP Venture Capital SGRPre Seed
Insight PartnersGrowth Equity, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 1, 2026

    Supported more than 450,000 patients across Europe.

  • Nov 12, 2024

    Monthly visitors increased 54% MoM, reaching 5.4 million.

Unobravo Filings

Explore SEC and related filing metadata, where available.

Unobravo filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Unobravo's valuation, stock price, and market status.

Is Unobravo a public or private company?

Unobravo is a private company.

What is the current stock price of Unobravo?

Unobravo is a private company, so its shares have no public market price. Caplight tracks Unobravo's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Unobravo worth (valuation)?

Unobravo's valuation is estimated at $189.0M based on funding round data.

Can I buy Unobravo stock?

Unobravo shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Unobravo's last funding round?

Unobravo's most recent funding round was Growth Equity on December 13, 2023.

Who are the main investors in Unobravo?

Key investors in Unobravo include Northzone, Insight Partners.

Will Unobravo IPO soon?

No public IPO plans have been announced for Unobravo.

How can I track Unobravo secondary market activity?

Caplight tracks bids, offers, and trades in Unobravo's shares on secondary markets.

Firmographic Details

HeadquartersNaples
Employee Range3,137
Year Founded2019
Last FundingDec 13, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?